GLP-1 drugs have transformed how doctors treat Type 2 diabetes, obesity, and cardiovascular disease — and Medicare beneficiaries across Northeast Florida are asking the same question: does my plan cover Ozempic, Wegovy, Mounjaro, or Zepbound? The answer depends on which drug you need, what condition it's prescribed for, and whether you qualify for a new federal program that started July 1, 2026.
What Are GLP-1 Drugs?
GLP-1 agonists (glucagon-like peptide-1 receptor agonists) are a class of medications that mimic a hormone involved in blood sugar regulation, appetite, and heart function. The most widely known names include:
- Ozempic (semaglutide) — FDA-approved for Type 2 diabetes
- Wegovy (semaglutide, higher dose) — FDA-approved for weight management and cardiovascular risk reduction
- Mounjaro (tirzepatide) — FDA-approved for Type 2 diabetes
- Zepbound (tirzepatide, higher dose) — FDA-approved for weight management
- Foundayo (orforglipron tablet) — FDA-approved for weight management (2026)
- Victoza / Trulicity — older GLP-1s approved for Type 2 diabetes
Medicare treats each of these drugs differently based on the condition they're prescribed to treat and the pathway through which coverage is provided.
The Medicare GLP-1 Bridge Program (July 1, 2026 – December 31, 2027)
Starting July 1, 2026, CMS launched a short-term demonstration called the Medicare GLP-1 Bridge. This program gives eligible Part D beneficiaries access to specific GLP-1 weight-loss medications at a flat $50-per-month copayment — regardless of income level.
Covered drugs under the Bridge program:
- Foundayo® (tablet)
- Wegovy® (injection or tablet)
- Zepbound® KwikPen® only — the single-dose Zepbound® vials and pens are not covered
Who is eligible? You must be 18 or older with Medicare Part D coverage and meet one of these BMI-based criteria when you begin GLP-1 therapy:
- BMI of 35 or higher (with no additional condition required)
- BMI of 30 or higher, plus at least one of: diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease (stage 3a or higher)
- BMI of 27 or higher, plus at least one of: prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms
Who is not eligible? You are excluded from the Bridge program if you already receive GLP-1 coverage through your Part D plan, or if you have Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. If you have diabetes, your Part D plan may still cover a GLP-1 for that condition — that is a separate pathway.
Important cost details: The $50 monthly copayment does not count toward your Part D deductible or your yearly out-of-pocket limit. Low-income subsidy (Extra Help) does not apply to Bridge program drugs, and these drugs are not eligible for the Medicare Prescription Payment Plan. Your doctor must submit a prior authorization form to CMS.
The Bridge program runs through December 31, 2027. CMS will use the data collected to inform future Part D coverage policy.
GLP-1 Coverage Through Your Regular Part D Plan
Separate from the Bridge program, your standard Part D plan may already cover certain GLP-1 drugs:
- For Type 2 diabetes: GLP-1 drugs approved for diabetes — such as Ozempic, Mounjaro, Victoza, and Trulicity — have long been covered by Part D when they appear on a plan's formulary and are prescribed for diabetes management. Coverage is subject to prior authorization, step therapy, and your plan's cost-sharing tier.
- For cardiovascular risk reduction: When the FDA approved Wegovy for reducing cardiovascular risk in adults with obesity and established cardiovascular disease, CMS clarified that this use falls outside the Part D weight-loss drug exclusion. Part D plans are permitted to include Wegovy on their formulary for this indication — but it is not mandatory. Whether your specific plan covers it depends on that plan's formulary decisions, and prior authorization with documentation of cardiovascular history is common.
Part D continues to exclude GLP-1 drugs prescribed solely for weight loss when no qualifying cardiovascular or diabetes condition is present — unless those drugs are accessed through the Bridge program.
How Medicare Advantage Plans Fit In
Medicare Advantage plans (Part C) with built-in drug coverage (MA-PD plans) participate in both coverage pathways. The Bridge program applies to MA-PD enrollees under the same eligibility rules as standalone Part D plans. For diabetes or cardiovascular-indication GLP-1s, the MA plan's own formulary rules apply — coverage and cost-sharing vary from plan to plan and county to county in Florida.
During the Annual Enrollment Period (October 15 – December 7), you can switch to a Part D or Medicare Advantage plan with better GLP-1 formulary coverage for the following year. A licensed agent can compare options side-by-side for your specific medications.
What Northeast Florida Seniors Should Ask
If your doctor has recommended a GLP-1 drug, here are the right questions to ask:
- Do I qualify for the Medicare GLP-1 Bridge program, and is my drug on the covered list?
- If not, is this drug on my Part D plan's formulary, and what is my expected monthly cost?
- Does my qualifying condition (Type 2 diabetes or cardiovascular disease) support regular Part D coverage?
- Does my plan require prior authorization, and what documentation will my doctor need to submit?
- Is there a lower-cost GLP-1 alternative on a preferred formulary tier?
At Green Insurance Agency in Orange Park, FL, we review your current plan's formulary, check your Bridge program eligibility, compare alternatives available in Clay County and Northeast Florida, and help you understand exactly what you'd pay — before you commit to any medication or plan change.
Does Medicare Cover GLP-1 Drugs? Bill Green Explains
Medicare Is NOT Covering Ozempic for Everyone — Bill Green Explains
Related Articles
View all Medicare Guide articles →From Our Blog
Need Help Understanding Your Options?
Our licensed agents at Green Insurance Agency provide free, personalized guidance. Whether you're new to Medicare or reviewing your current coverage, we're here to help.
